Change in frequency of vaso‐occlusive painful crises (as measured by pain diary days with significant pain) · people with sickle cell disease
1 finding from 1 review
HRQoL score (Child‐reported PedsQL generic scale) at 1 week · people with sickle cell disease
1 finding from 1 review
HRQoL score (Child‐reported PedsQL multidimensional fatigue scale) at 1 week · people with sickle cell disease
1 finding from 1 review
HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week · people with sickle cell disease
1 finding from 1 review
Length of hospital stay · people with sickle cell disease
1 finding from 1 review
Hypotension · people with sickle cell disease
Intravenous magnesium sulphate showed no clear difference in adverse effects: hypotension compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: warmth at infusion site · people with sickle cell disease
Intravenous magnesium sulphate may leads to higher adverse effects: warmth at infusion site compared with placebo (low certainty).
1 finding from 1 review
Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review
Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin leads to higher isolation of other micro‐organisms from the respiratory tract:… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review
Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).
1 finding from 1 review
Intervention not reported
Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
Respiratory exacerbations: number of days on intravenous antibiotics for respiratory exacerbations · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: inhaled corticosteroids changes respiratory exacerbations: number of days on intravenous antibiotics… compared with placebo (very low certainty).
1 finding from 1 review
Change in FEV1 % predicted at end of antibiotic course: absolute post‐treatment values · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in FEV1 % predicted at end of antibiotic course: absolute… compared with combination intravenous anti‐pseudomonal antibiotic therapy (low certainty).
1 finding from 1 review
Time to next course of antibiotics  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
Quality of life · adults and children with cystic fibrosis
1 finding from 1 review